2019
Connective Tissue Disease–Associated Interstitial Lung Disease Evaluation and Management
Antin-Ozerkis D, Hinchcliff M. Connective Tissue Disease–Associated Interstitial Lung Disease Evaluation and Management. Clinics In Chest Medicine 2019, 40: 617-636. PMID: 31376896, DOI: 10.1016/j.ccm.2019.05.008.Peer-Reviewed Original ResearchConceptsNonpharmacologic management strategiesMainstay of therapyConnective tissue diseaseInterstitial lung diseaseRate of progressionDisease activityTherapy initiationTissue diseaseRadiographic findingsLung diseaseDrug toxicityDisease severityDisease evaluationMultidisciplinary approachPatientsDiseaseImportant contributorImmunosuppressionMorbidityTherapyInfectionMainstayMortalityProgressionTrialsComplementary therapies for patients with systemic sclerosis
Showalter K, Hoffmann A, DeCredico N, Thakrar A, Arroyo E, Goldberg I, Hinchcliff M. Complementary therapies for patients with systemic sclerosis. Journal Of Scleroderma And Related Disorders 2019, 4: 187-199. PMID: 35382503, PMCID: PMC8922560, DOI: 10.1177/2397198319833503.Peer-Reviewed Original Research
2014
Systemic sclerosis: beyond limited and diffuse subsets?
Varga J, Hinchcliff M. Systemic sclerosis: beyond limited and diffuse subsets? Nature Reviews Rheumatology 2014, 10: 200-202. PMID: 24535544, PMCID: PMC5438483, DOI: 10.1038/nrrheum.2014.22.Peer-Reviewed Original Research